Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping

被引：28

作者：

Beck, Hans-Peter ^{[1
,2
]}

Wampfler, Rahel ^{[1
,2
]}

Carter, Nick ^{[4
]}

Koh, Gavin ^{[4
]}

Osorio, Lyda ^{[5
]}

Rueangweerayut, Ronnatrai ^{[6
]}

Krudsood, Srivcha ^{[7
]}

Lacerda, Marcus V. ^{[8
]}

Llanos-Cuentas, Alejandro ^{[9
,10
]}

Duparc, Stephan ^{[3
]}

Rubio, Justin P. ^{[4
]}

Green, Justin A. ^{[4
]}

机构：

[1] Swiss Trop & Publ Hlth Inst, Dept Med Parasitol & Infect Biol, Geneva, Switzerland

[2] Univ Basel, Geneva, Switzerland

[3] Med Malaria Venture, Geneva, Switzerland

[4] GlaxoSmithKline Res & Dev Ltd, Middlesex, Middx, England

[5] Univ Valle, Sch Publ Hlth, Cali, Colombia

[6] Mae Sot Gen Hosp, Amphoe Mae Sot, Tak Province, Thailand

[7] Mahidol Univ, Fac Trop Med, Bangkok 10700, Thailand

[8] Fdn Med Trop Doutor Heitor Vieira Amazonas Dourad, Manaus, Amazonas, Brazil

[9] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Lima, Peru

[10] Univ Peruana Cayetano Heredia, Sch Publ Hlth, Lima, Peru

来源：

JOURNAL OF INFECTIOUS DISEASES | 2016年 / 213卷 / 05期

关键词：

tafenoquine; Plasmodium vivax; genotyping; antihypnozoite; efficacy; GENETIC DIVERSITY; RELAPSE; INFECTIONS; FALCIPARUM; MALARIA; GUINEA;

D O I：

10.1093/infdis/jiv508

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Prevention of relapse of Plasmodium vivax infection is a key treatment goal in malaria. Use of P. vivax genotyping in a multicenter, double-blind, randomized, placebo-controlled phase 2b study in Peru, India, Thailand, and Brazil allowed determination of genetically heterologous or homologous P. vivax infection recurrence following receipt of chloroquine plus one of 4 doses of tafenoquine (50, 100, 300, or 600 mg) or chloroquine plus primaquine, compared with receipt of chloroquine alone. The antihypnozoite efficacy of tafenoquine was evident as a reduction in homologous recurrences of P. vivax infection as drug doses were increased. No clear dose-response pattern was evident for heterologous recurrences of P. vivax infection. Rates of homologous recurrence of P. vivax infection appear to be clinically useful for comparing drug efficacy for the prevention of P. vivax infection relapse.

引用

页码：794 / 799

页数：6

共 14 条

[11] Duffy Negative Antigen Is No Longer a Barrier to Plasmodium vivax - Molecular Evidences from the African West Coast (Angola and Equatorial Guinea) [J].